Universal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Tarsus by 19.9% in Q4 to 109,857 shares (about $8.995 million), representing roughly 0.26% of the company.
• Wall Street has a consensus rating of Moderate Buy with a $90.67 average target, but analyst opinions are mixed (two Strong Buy, four Buy, two Hold, one Sell).
• Tarsus beat Q4 revenue estimates ($151.67M vs. $144.56M) but missed EPS (-$0.20 vs. -$0.19) and remains unprofitable, while insiders sold about 79,391 shares (~$5.43M) over the past three months.

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,857 shares of the company's stock after buying an additional 18,267 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.26% of Tarsus Pharmaceuticals worth $8,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Tarsus Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company's stock worth $169,000 after acquiring an additional 431 shares during the period. Harbor Capital Advisors Inc. increased its position in Tarsus Pharmaceuticals by 39.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 21,722 shares of the company's stock valued at $1,779,000 after acquiring an additional 6,134 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Tarsus Pharmaceuticals by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 130,380 shares of the company's stock valued at $10,531,000 after acquiring an additional 1,643 shares during the period. SG Americas Securities LLC boosted its position in Tarsus Pharmaceuticals by 118.8% in the fourth quarter. SG Americas Securities LLC now owns 13,518 shares of the company's stock worth $1,107,000 after purchasing an additional 7,339 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Tarsus Pharmaceuticals in the third quarter worth about $248,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TARS shares. Zacks Research cut shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $98.00 target price for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $90.67.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $61.45 on Monday. The business's 50-day moving average price is $69.17 and its 200-day moving average price is $72.31. The stock has a market cap of $2.62 billion, a P/E ratio of -37.93 and a beta of 0.63. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The firm had revenue of $151.67 million during the quarter, compared to analysts' expectations of $144.56 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Activity

In other news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $68.79, for a total value of $859,875.00. Following the completion of the sale, the director directly owned 116,332 shares of the company's stock, valued at $8,002,478.28. This represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $283,477.00. Following the transaction, the general counsel owned 63,959 shares in the company, valued at approximately $4,285,253. This trade represents a 6.20% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 79,391 shares of company stock valued at $5,432,035. Company insiders own 8.97% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.